Health Ark Biopharmaceutical Secures Approval for ADHD Treatment Aizhida in China Shanghai Ark Biopharmaceutical Co., Ltd. has received approval from China’s National Medical Products Administration (NMPA) for its innovative ADHD treatment, Aizhida. The new drug... Editorial8 January, 2026